Refrakter trombositopeni ile seyreden Faktör V Leiden mutasyonu olan primer antifosfolipid sendromlu olguda eltrombopag deneyimi

Cilt: 10 Sayı: 1 1 Nisan 2017
  • Sinem Namdaroğlu
  • Şerife Solmaz Medeni
  • Tuğba Çetintepe
  • Ozan Barış Namdaroğlu
  • Oktay Bilgir
Pamukkale Tıp Dergisi Kapak
Pamukkale Tıp Dergisi
PDF İndir
EN TR

Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Öz

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disorder characterized by recurrent arterial or venous thrombosis, fetal loss, thrombocytopenia, neurological symptoms and presence of serum antiphospholipid antibodies (AFA). In this report,we present a young male patient with thrombocytopenia who was refractory to steroids, intravenous immunoglobulin and splenectomy but had complete response to eltrombopag treatment, FV Leiden heterozygous mutant positive, also had a history of sinüs thrombosis taking oral anticoagulant treatment has been diagnosed primary APS. Eltrombopag treatment primary antiphospholipid syndrome patient associated with refractory thrombocytopenia.

Anahtar Kelimeler

Ayrıntılar

Birincil Dil

İngilizce

Konular

-

Bölüm

-

Yazarlar

Sinem Namdaroğlu Bu kişi benim

Şerife Solmaz Medeni Bu kişi benim

Tuğba Çetintepe Bu kişi benim

Ozan Barış Namdaroğlu Bu kişi benim

Oktay Bilgir Bu kişi benim

Yayımlanma Tarihi

1 Nisan 2017

Gönderilme Tarihi

1 Nisan 2017

Kabul Tarihi

-

Yayımlandığı Sayı

Yıl 2017 Cilt: 10 Sayı: 1

IZ

https://izlik.org/JA77UN57PT

Kaynak Göster

RIS / Bibtex
APA
Namdaroğlu, S., Medeni, Ş. S., Çetintepe, T., Namdaroğlu, O. B., & Bilgir, O. (2017). Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal, 10(1), 67-72. https://izlik.org/JA77UN57PT
AMA
1.Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Tıp Derg. 2017;10(1):67-72. https://izlik.org/JA77UN57PT
Chicago
Namdaroğlu, Sinem, Şerife Solmaz Medeni, Tuğba Çetintepe, Ozan Barış Namdaroğlu, ve Oktay Bilgir. 2017. “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”. Pamukkale Medical Journal 10 (1): 67-72. https://izlik.org/JA77UN57PT.
EndNote
Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O (01 Nisan 2017) Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal 10 1 67–72.
IEEE
[1]S. Namdaroğlu, Ş. S. Medeni, T. Çetintepe, O. B. Namdaroğlu, ve O. Bilgir, “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”, Pam Tıp Derg, c. 10, sy 1, ss. 67–72, Nis. 2017, [çevrimiçi]. Erişim adresi: https://izlik.org/JA77UN57PT
ISNAD
Namdaroğlu, Sinem - Medeni, Şerife Solmaz - Çetintepe, Tuğba - Namdaroğlu, Ozan Barış - Bilgir, Oktay. “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”. Pamukkale Medical Journal 10/1 (01 Nisan 2017): 67-72. https://izlik.org/JA77UN57PT.
JAMA
1.Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Tıp Derg. 2017;10:67–72.
MLA
Namdaroğlu, Sinem, vd. “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”. Pamukkale Medical Journal, c. 10, sy 1, Nisan 2017, ss. 67-72, https://izlik.org/JA77UN57PT.
Vancouver
1.Sinem Namdaroğlu, Şerife Solmaz Medeni, Tuğba Çetintepe, Ozan Barış Namdaroğlu, Oktay Bilgir. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Tıp Derg [Internet]. 01 Nisan 2017;10(1):67-72. Erişim adresi: https://izlik.org/JA77UN57PT
Creative Commons Lisansı
Pamukkale Tıp Dergisi, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır